AMENDMENTS TO THE CLAIMS

In the Claims:

1. (Currently Amended) A pharmaceutical composition for oral administration, comprising:
   a. lithium carbonate,
   b. optional pharmacologic excipients,
   c. from about 5% (w/w) to about 15% (w/w) of at least one dissolution rate stabilizer, and
   d. at least one secondary release agent.

2. (Original) The pharmaceutical composition according to claim 1, wherein the lithium carbonate does not exceed a dose greater than about 450 mg/tablet.

3. (Original) The pharmacologic composition according to claim 1 additionally comprising iron oxide as a colorant, wherein the iron oxide does not exceed a level of about 1 mg/tablet.

4. (Original) The pharmaceutical composition according to claim 1, wherein the optional pharmacologic excipients further comprises at least one lubricant at a concentration of between about 0.1% and about 1.0% of the composition by weight.

5. (Original) The pharmaceutical composition according to claim 4 wherein said lubricant is selected from stearic acid, calcium stearate, magnesium stearate and sodium stearyl fumerate, said lubricant is at a concentration of about 0.1% to about 1.0% of the composition by weight.

6. (Original) The pharmaceutical composition according to claim 1, wherein the composition is compressed at a pressure of between about 7kPa to about 20 kPa.

7. (Original) The pharmaceutical composition according to claim 1, wherein the composition is compressed with a pressure not greater than about 7 kPa.

8. (Original) The pharmaceutical composition according to claim 1, wherein the at least one dissolution rate stabilizer comprises sodium carboxymethylcellulose.

9-10. (Canceled)

11. (Original) The pharmaceutical composition according to claim 1, wherein the at least one secondary release agent comprises glycine.

12. (Original) The pharmaceutical composition according to claim 11, wherein the glycine comprises between about 0.5 to about 40 mg/tablet.

13. (Original) The pharmaceutical composition according to claim 11, wherein the glycine comprises a level not greater than about 20 mg/tablet.

14. (Original) The pharmaceutical composition according to claim 11, wherein the glycine comprises a level not greater than about 14 mg/tablet.

15. (Original) The pharmaceutical composition according to claim 11, wherein the glycine comprises a level not greater than about 11 mg/tablet.

16. (Original) The pharmaceutical composition according to claim 11, wherein the glycine comprises a level not greater than about 2 mg/tablet.

17. (Currently Amended) A pharmaceutical composition for oral administration, comprising:

a. lithium carbonate,

b. iron oxide,

c. stearic acid,

d. from about 5% to about 15% (w/w) of sodium carboxymethylcellulose,
e. glycine and
f. optional pharmaceutically acceptable excipients.

18. (Original) A controlled release solid dosage form of lithium carbonate containing:

a. about 85% to about 90% by weight lithium carbonate,
b. about 10% to about 15% sodium carboxymethylcellulose,
c. about 0.5% glycine, and
d. optional pharmaceutically acceptable excipients.

19-60. (Canceled)

61. (New) A pharmaceutical composition for oral administration, comprising:

a. lithium carbonate,
b. optional pharmacologic excipients,
c. no more than about 5% (w/w) of at least one dissolution rate stabilizer, and
d. at least one secondary release agent.

62. (New) The pharmaceutical composition according to claim 61, wherein the at least one dissolution rate stabilizer comprises sodium carboxymethylcellulose.

63. (New) The pharmaceutical composition according to claim 61, wherein the at least one secondary release agent comprises glycine.